Botulinum Toxin: State of the Art

被引：142

作者：

Jankovic, Joseph ^{[1
,2
]}

机构：

[1] Baylor Coll Med, Parkinsons Dis Ctr, Houston, TX 77030 USA

[2] Baylor Coll Med, Dept Neurol, Movement Disorders Clin, Houston, TX 77030 USA

来源：

MOVEMENT DISORDERS | 2017年 / 32卷 / 08期

关键词：

botulinum toxin; dystonia; blepharospasm; hemifacial spasm; spasticity; tremor; tics; TECHNOLOGY-ASSESSMENT SUBCOMMITTEE; CRANIAL-CERVICAL DYSTONIA; NEUROTOXIN TYPE-A; FLU-LIKE SYMPTOMS; AMERICAN-ACADEMY; DOUBLE-BLIND; SPASTICITY; EFFICACY; THERAPEUTICS; IMMUNOGENICITY;

D O I：

10.1002/mds.27072

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Botulinun neurotoxin (BoNT) has emerged as one of the most multipurpose therapeutic agents in modern medicine with more clinical applications than any other drug currently on the market. Initially developed in the treatment of strabismus and neurologic movement disorders, the use of botulinun neurotoxin has been expanding during the past 3 decades to include the treatment of a variety of ophthalmologic, gastrointestinal, urologic, orthopedic, dermatologic, dental, secretory, painful, cosmetic, and other conditions. In addition to onabotulinumtoxinA (Botox), abobotulinumtoxinA (Dysport), incobotulinumtoxinA (Xeomin), and RimabotulinumtoxinB (Myobloc or NeuroBloc) there are other novel botulinun neurotoxin products currently in development. With a better understanding of the cellular mechanisms of botulinun neurotoxin and advances in biotechnology, future botulinun neurotoxin products will likely be even more effective and customized to the specific indication and tailored to the needs of the patients. (C) 2017 International Parkinson and Movement Disorder Society

引用

页码：1131 / 1138

页数：8

共 77 条

[11] Is there enough evidence to use botulinum toxin injections for bruxism management? A systematic literature review [J].